References
Guigonis V, Dallocchio A, Baudouin V, Dehennault M, Hachon-Le Camus C, Afanetti M, Groothoff J, Llanas B, Niaudet P, Nivet H, Raynaud N, Taque S, Ronco P, Bouissou F (2008) Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol 23:1269–1279
Suri M, Tran K, Sharma AP, Filler G, Grimmer J (2008) Remission of steroid-resistant nephrotic syndrome due to focal and segmental glomerulosclerosis using rituximab. Int Urol Nephrol 40:807–810
Nakayama M, Kamei K, Nozu K, Matsuoka K, Nakagawa A, Sako M, Iijima K (2008) Rituximab for refractory focal segmental glomerulosclerosis. Pediatr Nephrol 23:481–485
Filler G, Hansen M, LeBlanc C, Lepage N, Franke D, Mai I, Feber J (2003) Pharmacokinetics of mycophenolate mofetil for autoimmune disease in children. Pediatr Nephrol 18:445–449
Allison AC, Eugui EM (1996) Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant 10:77–84
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sharma, A.P., Filler, G. Role of mycophenolate mofetil in remission maintenance after a successful response to rituximab. Pediatr Nephrol 24, 423–424 (2009). https://doi.org/10.1007/s00467-008-1030-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00467-008-1030-8